Investigational new drugMitochondrial Peptide
Compound 61438
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061438
Risk Class
HIGH
Last Audit
Feb 9, 2108
Research Abstract
Mitochondrial Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61438 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in investigational new drug with a high risk rating, meaning it is restricted to black-box teams with hardened compliance.
Supply records cite CAS AUTO-061438 with updates logged 2108-02-09.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61438Mitochondrial Peptide Program 61438
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061438
- [2] Operations Pulse • Mitochondrial Peptide innovation track
- [3] Risk Governance Ledger • HIGH clearance for COMPOUND-61438